MMS22L and gastric cancer: As a result, 12 genes were found to be downregulated following gilteritinib therapy, including CENPE, MCM4, GSPT1, MMS22L, DDX21, VDAC1, FDX1, OPA1, PDHX, ELOA, BCL3, and RACGP1, in EC, OC and GC TCGA cohort (Supplemental Fig. 4).